8 Deal Points That Kill Lower Middle Market Deals

Deal Point #3: Long-Term Capital
(aka “Patient Capital”)

Excerpted from https://privatedealteam.birthingofgiants.com/longterm-capital

Private Equity was built on a simple, predictable framework: deploy capital, improve operations, and sell—usually all within a 5 to 7 year window. It’s a model that has generated enormous wealth, reshaped industries, and created sophisticated methods of value extraction.

But here’s the problem: It was never designed to create generational companies.

As more founders and leaders approach me to discuss the future of their businesses, I see a clear shift in priorities. They’re looking for partners who can help them build enterprises that last—not deals that simply “mature” on schedule.

And that’s where patient capital comes in.

The Problem With the Traditional 7-Year Fund

A conventional private equity fund is a legally binding structure with a fixed lifespan—typically 5 to 7 years. That countdown clock drives everything:

• Investment Period: Identify and acquire companies quickly.

• Value Creation Period: Execute improvements—fast.

• Exit Period: Sell the company, ready or not.

Once the clock starts, the pressure builds. The general partner must return capital to its limited partners on schedule, regardless of market conditions or what might be best for the company’s long-term trajectory.

That means:

• Strategic decisions often prioritize short-term optics over long-term investments.

• Leadership teams are nudged to optimize for the exit.

• Big, foundational projects—those that take time to bear fruit—are deprioritized or abandoned.

In short, the model incentivizes speed over stewardship.

Patient Capital: The Long-Term Alternative

Patient capital vehicles—often backed by family offices, sovereign wealth funds, or public holding companies—operate without an expiration date. They don’t buy businesses with the goal of selling in a few years. They buy with the intention to own, compound, and grow for decades.

This flexibility unlocks a very different kind of strategy:

• Investments in R&D that may take years to commercialize

• Infrastructure upgrades with long-term productivity payoffs

• Strategic acquisitions designed for enduring market advantage

With no forced exit, the fund can behave like a true owner-operator.

This alignment resembles the philosophy made famous by Berkshire Hathaway: patient capital plus long-term thinking equals extraordinary compounding.

Two Models, Two Mindsets

At its core, the debate between traditional private equity and patient capital is a debate about time.

The 7-Year Fund Model

• Transaction-driven

• Measures success by IRR at exit

• Incentivizes short-term optimization

• Built for liquidity events

The Patient Capital Model

• Value-creation-driven

• Measures success by long-term compounding

• Incentivizes sustainable growth

• Built for legacy and longevity

This difference changes everything—from how capital is allocated to how leaders are compensated. When you remove the pressure to sell, you make space for decisions that benefit the company, its employees, and its customers over the long haul.

Why Founders Are Increasingly Choosing Patient Capital

More founders today aren’t simply looking to “cash out.” They’re looking for partners who will help protect their culture, their legacy, and the strategic foundation they’ve spent years—or decades—building.

Patient capital offers them:

• Time to execute ambitious visions

• Stability to plan beyond economic cycles

• Alignment with investors who think in decades, not quarters

In my view, this model isn’t just an option—it’s the future for companies that want to grow with intention rather than urgency.

Final Thought

The most transformative companies of the next generation won’t be built on a countdown clock. They’ll be built with patient capital, strategic discipline, and partners who measure success in decades.

Patient capital allows us to stop thinking like dealmakers—and start thinking like builders.

If you’re a founder considering your next chapter, it may be time to rethink what kind of capital partner will help you create the legacy you truly want.